| 摘要 |
PROBLEM TO BE SOLVED: To provide most critical assessment of the impact and utility of fixed dosing of a humanized IgG1 monoclonal antibody on pharmacokinetics and target drug concentrations.SOLUTION: In a first aspect, the invention provides a method for treating cancer comprising administering one or more fixed doses of a HER antibody, such as pertuzumab to a human patient in an amount effective to treat the cancer. In another aspect, the invention provides a method for treating cancer in a human patient comprising administering at least one fixed dose of pertuzumab to the patient, wherein the fixed dose is selected from the group consisting of 420 mg, 525 mg, 840 mg, and 1,050 mg of pertuzumab. |
